A Phase 2 interventional study of Medroxyprogesterone acetate + Atorvastatin in Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I, sponsored by Peking University People's Hospital. Recruiting at 1 site in China. Open to female participants aged 17 Years to 45 Years. Per ClinicalTrials.gov, last updated 2024-07-11.
Sponsored by Peking University People's Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Endometrial Hyperplasia with a site in China — 14 open to participants now, 15 under way, 5 of them phase 3. Endometrial Hyperplasia · China.
Among the 22 studies in Endometrial Hyperplasia with a site in China, this one is the 8th largest by planned enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2023, is one of 7 in phase 2, reaches primary completion later than 2 of the 14 other live ones, and was the 11th registered.
110 studies on the registry are indexed under Endometrial Hyperplasia; 38 are open to participants now.
Browse Endometrial Hyperplasia studies →14 of the 22 studies in Endometrial Hyperplasia with a site in China are open now. Recruiting first, the newest first:
Guizhou Provincial People's Hospital · Sites in China
Ages up to 18 · Women only · Healthy volunteers
Wang Jianliu · Sites in China
Ages 18–45 · Women only
Wenwen Wang · Sites in China
Ages 18–80 · Women only
Women's Hospital School Of Medicine Zhejiang University · Sites in China
Ages 18–45 · Women only
Peking University People's Hospital · Sites in China
Ages 17–45 · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 21 Endometrial Hyperplasia studies recruiting now, 9 (43%) set no upper age limit and 11 (52%) stop at 75 or younger; 7 take children under 18; 3 take healthy volunteers.
This study: 17 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 16 · Phase 3 11
First in 2013; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 82 is close to the median of 80 across 71 interventional studies indexed under Endometrial Hyperplasia.
Median enrollment 75 across the 19 interventional studies, 512 across the 3 observational. Of the 6 that completed or were terminated, 1 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 22 have an industry lead sponsor. The 10 most frequent:
Peking University People's Hospital is the lead sponsor of 611 studies on the registry; 248 are open to participants now.
Peking University People's Hospital has 5 studies filed under Endometrial Hyperplasia — fewer than ten, so there is no comparison to draw.
2 of the studies in Endometrial Hyperplasia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07892755Guizhou Provincial People's HospitalLiquid Biopsy-Based Early Screening for Endometrial Cancer in Regional Chinese Populations | 2027-08-09 |
| NCT07714070Peking University People's HospitalOrlistat Plus Progestin for Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies in Endometrial Hyperplasia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To explore the treatment efficacy of medroxyprogesterone acetate plus atorvastatin in patients with atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EEC) for conservative treatment.
After diagnosed of AEH or EEC by hysteroscopy, patients meet the study criteria will be enrolled. The lipid content (lipid droplet, cholesterol and triglyceride) in endometrial lesion tissue was detected by Raman scattering instrument. And Age, height, weight, waistline, blood pressure, basic history of infertility and family cancer will be collected. Blood tests, including fasting blood glucose (FBG), fasting insulin (FINS), blood lipids, sex hormone levels, anti-müllerian hormone (AMH) and renal/liver function tests will be performed before treatment to evacuate their basic conditions. Each subject will receive body fat testing by Inbody 770.
Patients will receive MPA (Medroxyprogesterone acetate) 250-500 mg by mouth daily plus atorvastatin 20mg by mouth daily for at least 3 months. Then hysteroscopy will be used to evaluate the endometrial condition every 3 months, and intra-operative findings will be recorded. Complete response (CR) is defined as the reversion of endometrial atypical hyperplasia to proliferative or secretory endometrium; partial response (PR) is defined as regression to hyperplasia with or without atypic; stable disease (SD) is defined as the persistence of the disease; and progressive disease (PD) is defined as the appearance of higher pathological progression, or myometrial invasion, or extra-uterine metastasis. Continuous therapies will be needed in PR. Patients with PD will be recommended for hysterectomy.
For patients remained SD after 9 months of treatment but refused hysterectomy, a multiple disciplinary discussion would be held for individual case, and alternative treatment would be given. Three months of maintenance treatment will be recommended for patients with CR, and participants will be followed up for at least 1 year.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MPA + Atorvastatin
Drug: Medroxyprogesterone acetate + Atorvastatin
MPA
Drug pages: Medroxyprogesterone AcetateStudies of Medroxyprogesterone AcetateMedroxyprogesterone Acetate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · AtorvastatinStudies of AtorvastatinAtorvastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
MPA (at a dosage of 250-500 mg/day,) + Atorvastatin (at a dosage of 20 mg/day), by mouth,
Pathological cumulative complete response rate;
3 to 4 months: From date of initial therapy until the date of CR or date of hysterectomy,
Time frame: assessed up to 4 months
Pathological cumulative complete response rate;
From 6 to 8 months; From date of initial therapy until the date of CR or date of hysterectomy,
Time frame: assessed up to 8 months
The lipid content (lipid droplet, cholesterol and triglyceride) in endometrial lesion tissue
The lipid content (lipid droplet, cholesterol and triglyceride) in endometrial lesion
Time frame: assessed up to 4 months
Overall complete response rate
Pathological response duration
Time frame: up to 2 years
Pathological response rate classified by different blood lipid level
Pathological response rate classified by different blood lipid level
Time frame: up to 2 years;
Relapse rate
Relapse rate
Time frame: up to 15 months after the end of treatment
Pregnancy rate
Pregnancy rate
Time frame: up to 15 months after the end of treatment
Toxic Side Effect
Toxicity evaluation according to CTCAE 5.0 version.
Time frame: up to 3 months after the end of treatment
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2023 (actual). Primary completion is estimated for Aug 2025, 31 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Medroxyprogesterone Acetate · Atorvastatin
Peking University People's Hospital →